Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. (NASDAQ: NTRB, NASDAQ: NTRBW) generates news primarily around the development of its prescription transdermal pharmaceutical products and its proprietary AVERSA abuse-deterrent transdermal technology. The company’s updates frequently focus on its lead product under development, an abuse-deterrent fentanyl transdermal system known as AVERSA FENTANYL, and on efforts to address the risks of abuse, diversion, misuse, and accidental exposure associated with transdermal opioid therapies.
News about Nutriband often covers clinical and regulatory milestones, such as meetings with the U.S. Food and Drug Administration (FDA) to discuss Chemistry, Manufacturing, and Controls plans, regulatory pathways under the 505(b)(2) NDA framework, and feedback on studies designed to characterize abuse-deterrent properties. Press releases also highlight patent developments, including Notices of Allowance, newly issued patents for abuse and misuse deterrent transdermal systems, and provisional patent applications intended to enhance AVERSA’s aversive formulations and coating methods.
Investors following NTRB and NTRBW can also expect corporate and strategic news, including stock dividends of Series A Convertible Preferred Stock, exercises of stock options and warrants, and transactions such as the agreement to sell a majority interest in the Pocono Pharmaceutical subsidiary to EarthVision Bio. Nutriband’s communications may additionally cover index inclusions, shareholder letters discussing milestones and outlook, and participation in investor conferences where management presents operational highlights and the strategic direction of the AVERSA platform.
This news page aggregates these developments into a single feed, allowing readers to review Nutriband’s announcements on product development, intellectual property, regulatory interactions, capital structure, and strategic initiatives related to its abuse-deterrent transdermal technology and lead fentanyl patch program.
Nutriband (NASDAQ:NTRB), a developer of transdermal pharmaceuticals and technology, will host an exclusive live investor webinar on May 30, 2024, at 4:15 p.m. ET.
Organized by RedChip Companies, the event will feature Chairman Serguei Melnik and CEO Gareth Sheridan, who will provide insights into the company's current operations and future milestones.
Investors can register for the free webinar and submit questions beforehand or during the live session.
Nutriband announced the appointment of Sergei Glinka to its board of directors. Glinka, an experienced business leader, brings a wealth of experience from his roles in major European companies. The Glinka family has invested $4.5 million in Nutriband via a private placement in April 2024, which totaled $8.4 million. Nutriband aims to use these funds to complete the FDA approval process for its AVERSA™ technology. AVERSA™, currently patented in 45 countries, is projected to reach peak annual US sales between $80 million and $200 million. The global opioid market was valued at $22.8 billion in 2022.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.